NL-OMON45189已完成3 期
Early treatment of central serous retinopathy by photodynamic therapy. A randomized controlled trial. - CSR & PDT
Oogziekenhuis Rotterdam0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •Age > 18 years.
- •Informed consent.
- •Poor prognositic acute CSR.
排除标准
- •History of CSR in either eye.
- •Allergy to fluorescein dyes.
- •Allergy to visudyne.
- •Opaque ocular media, impairing regular fundus imaging
- •Other ocular disorder possibly reducing visual acuity
研究者
相似试验
已完成
不适用
Early treatment of central serous retinopathy by photodynamic therapy. A randomized controlled trial.Central serous retinopathy.NL-OMON20530Het Oogziekenhuis RotterdamSchiedamse Vest 180 3011 BH Rotterdam Nederland60
已完成
不适用
ong term follow-up of central serous retinopathy. An observational case series.central serous retinopathy10047060NL-OMON31151Oogziekenhuis Rotterdam100
已完成
1 期
Topical Interferon Gamma-1b for Central Serous ChorioretinopathyRetinal DiseaseMacular DiseaseNCT01468337National Eye Institute (NEI)5
进行中（未招募）
1 期
Treatment of macular edema due to central retinal vein occlusion with ranibizumab (Lucentis®). - Lucentis in CRVOThis case-series is designed to evaluate the safety and efficacy of intravitreal ranibizumab (Lucentis®) in the treatment of macular edema due to central retinal vein occlusion.MedDRA version: 12.1Level: LLTClassification code 10007972Term: Central retinal vein occlusionMedDRA version: 12.1Level: LLTClassification code 10054467Term: Macular edemaEUCTR2009-017782-30-ATMedizinische Universität Graz, Universitäts-Augenklinik
招募中
2 期
Intraretinal vessel treatment for central retinal vein occlusioCetntral Retinal Artery and Vein OcclusionJPRN-UMIN000007958Intraretinal vessel treatment for central retinal vein occlusion study team10